Salute e Benessere
Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight
Discover which open-angle glaucoma medications are expected to grab the market share @
Prevalence of open-angle glaucoma increases sharply with age, and global demographic shifts (larger elderly populations) are a primary long-term demand driver for diagnostics, chronic therapies, and surgical interventions. In the US, at least individuals aged 40 and older have been diagnosed with glaucoma. This number represents a significant public health concern.
Improved screening programs, wider use of OCT and tele-ophthalmology, and growing awareness mean more early diagnoses, which increases lifetime treatment uptake (drops, combination therapy, procedures). This enlarges the addressable treated population even where the underlying incidence is stable.
In OAG, like ZIOPTAN and such as OMLONTI remain key intraocular pressure-lowering therapies. Beta-blockers, alpha agonists, and carbonic anhydrase inhibitors support conventional management. Emerging options include , which has been studied for its , targeting intraocular pressure-independent pathways.
Minimally invasive glaucoma surgery (MIGS) devices like are increasingly used for patients needing surgical intervention, offering a safer profile compared to traditional filtering surgeries.
The anticipated launch of open-angle glaucoma drugs such as (Omikron Italia), (Amydis), (PolyActiva Pty), (Perfuse Therapeutics), (AbbVie), and others will change the dynamics of the open-angle glaucoma market in the next 10 years.
The treatment landscape for open-angle glaucoma has advanced considerably, though intraocular pressure (IOP) reduction remains the cornerstone of disease management. Current therapies include FP receptor agonists such as , which promote uveoscleral outflow, and beta-blockers like timolol, which suppress aqueous humor production. Additionally, IOP-lowering options are provided by alpha agonists (e.g., brimonidine) and carbonic anhydrase inhibitors (e.g., dorzolamide).
More recent entrants, including , an EP2 receptor agonist, and , a Rho kinase inhibitor, introduce novel mechanisms to improve trabecular outflow and may offer neuroprotective effects. To improve adherence and ensure sustained delivery, long-acting solutions such as , a bimatoprost intracameral implant, have been developed, enabling extended IOP control with a single administration and minimizing reliance on daily drops. Furthermore, minimally invasive glaucoma surgery (MIGS) devices, such as the , are gaining traction as surgical options, providing safer alternatives to conventional filtering procedures.
Learn more about the open-angle glaucoma treatment options @
The emerging OAG drugs in clinical trials include (Omikron Italia), (Amydis), (PolyActiva Pty), (Perfuse Therapeutics), (AbbVie), and others.
exhibits a multifaceted mechanism of action, involving the preservation of cardiolipin and sphingomyelin, restoration of phosphatidylcholine, stimulation of glutathione production, reduction of glutamate levels, and improvement of mitochondrial function, among other effects. It is currently undergoing Phase II clinical development for patients with open-angle glaucoma.
The utilizes PolyActiva's proprietary Prezia Sustained Drug Delivery Technology to deliver a steady daily dose of latanoprost free acid. This system is specifically engineered to achieve features not possible with conventional blend technologies, such as zero-order drug release and rapid, complete, and non-toxic biodegradation following treatment completion. The implant is presently in Phase II clinical trials for primary open-angle glaucoma.
In December 2024 , PolyActiva reported encouraging Phase II trial outcomes for PA5108. The study achieved its primary efficacy and safety endpoints, demonstrating significant reductions in intraocular pressure over 26 weeks. The company noted that these findings mark an important milestone in its mission to deliver long-term, dependable drug delivery solutions for patients with primary open-angle glaucoma.
The anticipated launch of these emerging open-angle glaucoma therapies are poised to transform the open-angle glaucoma market landscape in the coming years. As these cutting-edge open-angle glaucoma therapies continue to mature and gain regulatory approval, they are expected to reshape the open-angle glaucoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about new treatment for open-angle glaucoma, visit @
Open-angle glaucoma (OAG) is a chronic, progressive, and irreversible optic neuropathy with multiple contributing factors. An open anterior chamber angle, characteristic changes in the optic nerve head, thinning of the retinal nerve fiber layer, and gradual peripheral vision loss define it. In advanced stages, central vision may be affected, potentially leading to blindness. Elevated intraocular pressure (IOP) is a key risk factor and the primary therapeutic target, though the disease typically affects both eyes, with asymmetry influenced by underlying causes. While an IOP greater than 21 mm Hg is strongly linked to glaucoma, not all individuals with ocular hypertension develop optic nerve damage. Research has shown that many remain asymptomatic, preserving normal visual fields and healthy optic nerves despite elevated pressure.
The open-angle glaucoma market forecast is derived using patient-based forecasts and analysis. The report offers in-depth analysis of the historical and current open-angle glaucoma patient pool and forecasted trends for the leading markets (the US, EU4, UK, and Japan ). It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The open-angle glaucoma market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets (the US, EU4, UK, and Japan ) segmented into:
Download the report to understand which factors are driving open-angle glaucoma epidemiology trends @
Discover more about open-angle glaucoma drugs in development @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key open-angle glaucoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucoma companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glaucoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key primary open angle glaucoma companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/open-angle-glaucoma-market-outlook-brightens-as-emerging-therapies-reshape-treatment-paradigms--delveinsight-302550763.html